Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1Phase 1 1

Status

Completed 4Recruiting 3Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1

Conditions

Breast Neoplasms 183Carcinoma, Non-Small-Cell Lung 141Multiple Myeloma 120Prostatic Neoplasms 116Leukemia, Myeloid, Acute 74Colorectal Neoplasms 74Neoplasms 73Melanoma 71Squamous Cell Carcinoma of Head and Neck 66Lymphoma 64Lung Neoplasms 64Neoplasm Metastasis 62Pancreatic Neoplasms 55Ovarian Neoplasms 50Sarcoma 45Carcinoma, Renal Cell 45Triple Negative Breast Neoplasms 42Leukemia, Lymphocytic, Chronic, B-Cell 42Urinary Bladder Neoplasms 41Glioblastoma 41Carcinoma, Hepatocellular 41Recurrence 40Head and Neck Neoplasms 37Lymphoma, Large B-Cell, Diffuse 35Brain Neoplasms 35Myelodysplastic Syndromes 34Hematologic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Lymphoma, Non-Hodgkin 33Lymphoma, Mantle-Cell 32

Interventions

Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Adenocarcinoma, Clear Cell × Clear all
NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Brown University

Phase 2 Active not recruiting
46 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT05032040 2025-02-07

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Xencor, Inc.

Phase 2 Active not recruiting
170 enrolled
GenitourinaryGynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡